Aldeyra positive Phase 2 ADX-629 in alcohol-hepatitis; pipeline focuses on ADX-248/ADX-246; cash runway into H2 2027

Aldeyra Therapeutics, Inc.

ADX-629 Phase 2 trial in mild-to-moderate alcohol-associated hepatitis showed significant improvement in MELD score (P=0.001), triglycerides (P<0.0001), and CRP (P<0.0001).
Pipeline focused on next-generation RASP modulators ADX-248 (metabolic inflammation, IND 2026) and ADX-246 (dry AMD, IND 2026); ADX-629 development discontinued.
Cash runway extended into second half of 2027 due to pipeline prioritization.
No serious adverse events reported in the ADX-629 trial; drug was well tolerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.